// App-Quantinova.ai

S181 : DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL

Researchers

Presenter

  • Martin Kaiser

Principal Investigators

  • Andrew Hall

  • Katrina Walker

  • Ruth de Tute

  • Roberts Sadie

  • Emma Ingleson

  • Kristian Bowles

  • Mamta Garg

  • Anand Lokare

  • Christina Messiou

  • Graham Jackson

  • Guy Pratt

  • Gordon Cook

  • Mark Drayson

  • Roger Owen

  • Sarah Brown

  • Matthew Jenner

Medical Centers

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • St James Hospital, Leeds, United Kingdom

  • University of Birmingham, Birmingham, United Kingdom

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • Institute for Cancer Research, London, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • University of Leeds, Leeds, United Kingdom

  • The Royal Marsden Hospital &amp

  • Birmingham Heartlands Hospital,Birmingham,United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Primary plasma cell leukemia

  • High-risk myeloma

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

  • Sparsentan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03188172

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved